+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04892953

Evaluating Local Consolidative Therapy and Durvalumab with Chemotherapy Options for Progressive Stage III Non-Small Cell Lung Cancer After Chemoradiation

Led by M.D. Anderson Cancer Center · Updated on 2026-09-03

51

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating local consolidative therapy LCT combined with durvalumab in patients with stage III non-small cell lung cancer NSCLC who have either three or fewer progressing lesions oligoprogressive or more than three lesions polyprogressive after receiving chemoradiation and anti-PD-L1 therapy. This phase II trial aims to assess the effect of these treatments on progression-free survival compared to historical controls, along with overall survival, patterns of disease progression, quality of life, and safety. Participants are assigned to one of two groups based on their disease progression type. Cohort A oligoprogressive receives LCT, which may include radiation therapy andor surgery, followed by durvalumab given intravenously every 28 days. Cohort B polyprogressive also undergoes LCT, then receives durvalumab plus chemotherapy options such as carboplatin combined with paclitaxel, nab-paclitaxel, or gemcitabine in cycles repeated every 21 days for up to four cycles non-squamous patients receive additional pemetrexed therapy. After completing treatment, participants are monitored every 12 weeks for two years. During the study, participants undergo regular assessments including imaging scans, biopsies, blood and stool samples for biomarker and microbiome analysis, and quality-of-life questionnaires. Researchers track progression-free survival for up to two years from LCT initiation, overall survival, and rates of disease progression in different lung regions. Safety and tolerability of the treatments are closely monitored, and participants are followed long-term to evaluate treatment impact and disease control.

CONDITIONS

Brief Title

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here